| Literature DB >> 31463438 |
Hussain Noorwali1,2,3, Michael P Grant2, Laura M Epure2, Padma Madiraju2, Hee-Jeong Sampen4, John Antoniou1,2, Fackson Mwale1,2.
Abstract
Neurotrophins (NTs) are the major contributors of sensory axonal sprouting, neural survival, regulation of nociceptive sensory neurons, <span class="Disease">inflammatory hyperalgesia, and <span class="Disease">neuropathic pain. Intervertebral disc (IVD) cells constitutively express NTs. Their expression is upregulated by proinflammatory cytokines present in the IVD during degeneration, which can promote peripheral nerve ingrowth and hyperinnervation, leading to discogenic pain. Currently, there are no targeted therapies that decrease hyperinnervation in degenerative disc disease. Link N is a naturally occurring peptide with a high regenerative potential in the IVD. Therefore, the suitability of Link N as a therapeutic peptide for suppressing NTs, which are known modulators and mediators of pain, was investigated. The aim of the present study is to determine the effect of Link N on NTs expression, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and their cognate receptors TrkA and TrkB as they are directly correlated with symptomatic back pain. Furthermore, the neurotransmitter (substance P) was also evaluated in human annulus fibrosus (AF) cells stimulated with cytokines. Human AF cells isolated from normal IVDs were stimulated with interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) in the presence or absence of Link N. NGF release in the media was evaluated by Western blotting. Total RNA was isolated and gene expression was measured using real-time PCR. Gene expression of NGF, BDNF, TrkA, and TrkB significantly decreased in human disc cells stimulated with either IL-1β or TNF-α supplemented with Link N when compared to the cells stimulated only with IL-1β or TNF-α. NGF protein expression was also suppressed in AF cells coincubated with Link N and IL-1β when compared to the cells stimulated only with IL-1β. Link N can suppress the stimulation of NGF, BDNF, and their receptors TrkA and TrkB in AF cells in an inflammatory milieu. Thus, coupled with previous observations, this suggests that administration of Link N has the potential to not only repair the discs in early stages of the disease but also suppress pain.Entities:
Keywords: Link N; discogenic pain; intervertebral disc; low back pain
Year: 2018 PMID: 31463438 PMCID: PMC6686832 DOI: 10.1002/jsp2.1008
Source DB: PubMed Journal: JOR Spine ISSN: 2572-1143
Figure 1Expression of nerve growth factor (NGF) by immunohistochemistry in annulus fibrosus (AF) cells from Thompson grading intervertebral discs (IVDs). Representative images of AF cells from human discs grades 2 to 4 expressing NGF (arrows indicating the brown staining). IgG was used as a negative control. Bars represent means +/‐ SEMs; ANOVA post hoc Dunnett's, Grade 2 was used as the control. **, p < 0.01; ***, p < 0.001
Figure 2Analysis of newly synthesized nerve growth factor (NGF) in the discs. A, Western blot analysis of NGF in human discs from grades 2 to 4 from the annulus fibrosus (AF). B, Semiquantitative analysis of NGF. Means ± SEMs; n = 3. anova, post hoc Dunnetts’s; **P < .01
Figure 3Analysis of nerve growth factor (NGF) released in the media. A, Western blot analysis of NGF protein released by annulus fibrosus (AF) degenerative cells exposed to Link N (LKN), interleukin‐1β (IL‐1β), or coexposed to Link N and IL‐1β (LKN + IL‐1β). B, Semiquantitative analysis of NGF. Means ± SEMs; n = 3. anova, post hoc Dunnetts’s; ****P < .0001
Figure 4Effect of Link N on IL‐1β‐induced nerve growth factor (NGF), BDNF gene expression. Changes in NGF, TrkA, brain‐derived neurotrophic factor (BDNF), and TrkB gene expression in normal human annulus fibrosus (AF) cells after 48 hours exposure to Link N (1 μg/mL) + interleukin‐1β (IL‐1β) (10 ng/mL) or IL‐1β (10 ng/mL) alone. The results are shown as means ± SE (n = 3; anova, post hoc Dunnetts’s; *P < .05; **P < .01; ****P < .0001)
Figure 5Effect of Link N on IL‐1β‐induced substance P (SP) gene expression. Changes in TAC1, and TAC1R gene expression in normal human annulus fibrosus (AF) cells after 48 hours exposure to Link N (1 μg/mL) + interleukin‐1β (IL‐1β) (10 ng/mL) or IL‐1β (10 ng/mL) alone supplementation. The results are shown as means ± SE (n = 3; anova, post hoc Dunnetts’s; *P < .05; ***P < .001)
Figure 6Effect of Link N on tumor necrosis factor‐α (TNF‐α)‐induced nerve growth factor (NGF), BDNF gene expression. Changes in NGF, TrkA, brain‐derived neurotrophic factor (BDNF), and TrkB gene expression in normal human annulus fibrosus (AF) cells after 48 hours exposure to Link N (1 μg/mL) + TNF‐α (100 ng/mL) or TNF‐α (100 ng/mL) alone. The results are shown as means ± SE (n = 3; anova, post hoc Dunnetts’s; *P < .05; **P < .01; ***P < .001)
Figure 7Effect of Link N on tumor necrosis factor‐α (TNF‐α)‐induced substance P (SP) gene expression. Changes in TAC1 and TAC1R gene expression in normal human annulus fibrosus (AF) cells after 48 hours exposure to Link N (1 μg/mL) + TNF‐α (100 ng/mL) or TNF‐α (100 ng/mL) alone supplementation. The results are shown as means ± SE (n = 3; anova, post hoc Dunnetts’s; *P < .05; ***P < .001)
Link N is an ideal intervertebral disc (IVD) target profile
| Product element | Link N | Anelgesic/anti‐inflammatory | Steroids | Biologics |
|---|---|---|---|---|
| Increase disc/matrix synthesis |
| X | X |
|
| Decrease disc degeneration |
| X | X |
|
| Reduce inflammation |
|
|
|
|
| Active in inflammatory environment |
|
|
|
|
| Reduce pain |
|
|
|
|
| Nonosteogenic |
|
|
| X |
| Lost lasting effects |
| X | X |
|
| Limited or no long‐term side effects |
| X | X | ? |
| Cost effective |
|
|
| X |
Ideal characteristics of an IVD therapeutic.
Clinical scenario in which Link N can be used
|
|
| Discectomies |
| Removal of bulging disc material relieves pain but does not encourage regeneration/repair |
| Younger population treatment, earlier stage, prone to further degeneration if no repair is induced |
| Spinal fusions |
| Performed at advanced levels of disc degeneration |
| Often leads to further degeneration in adjacent discs by altering biomechanics/kinematics |
|
|
| In conjunction with/replacement for steroid injections |
| Known short‐term benefits of steroids, but long‐term effectiveness was less established |
| Steroids may address acute inflammation and allow the body’s normal healing process to lead to long‐term improvement, but do not cause disc repair |